ReviewCA: a cancer journal for clinicians
MicroRNAome genome: a treasure for cancer diagnosis and therapy.
Review in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02964351 (microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer), which is not on this map. Cited by 297 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer
Who cites it
297 citing papers in PubMed, 4 syntheses or guidelines pooled it, 537 citations in OpenAlex.
- Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.British journal of cancer · 2024Pooled it
- Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis.Frontiers in neurology · 2020Pooled it
- The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis.BioMed research international · 2019Pooled it
- Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis.EBioMedicine · 2018Pooled it
- Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population.BioMed research international · 2019Trial
- Article
- OM-sqPCR enables one-step multiplex quantification of circulating small-RNA subclasses for colorectal cancer classification.iScience · 2026Article
- MicroRNA-181a-5p promotes papillary thyroid carcinoma progress via the PTEN/AKT pathway.Molecular biotechnology · 2026Article
- miR-486-5p suppresses autophagy in hepatocellular carcinoma via activation of the AKT/mTOR signalling pathway.Molecular biomedicine · 2026Article
- Review
- MicroRNA-mediated modulation of cancer-associated fibroblasts in HER2-positive breast tumor microenvironment: a comprehensive review.Discover oncology · 2026Review
- Tumor microenvironment-driven microRNA dysregulation: Key interactions in colorectal cancer progression.World journal of gastrointestinal oncology · 2026Review
- Article
- Hypermethylation of microRNA-34c CpG Island predicts unfavorable prognosis in acute myeloid leukemia.Scientific reports · 2025Article
- Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients.Breast cancer research : BCR · 2025Article
- Micro-RNA-140-3p Acts as a Tumor Suppressor Gene in Acute Promyelocytic Leukemia by Targeting Hepatocyte Growth Factor.Cell biochemistry and biophysics · 2025Article
- Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms.Clinical epigenetics · 2025Review
- Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions.Infectious agents and cancer · 2025Review
- Application of non‑coding RNAs in tumors (Review).Molecular medicine reports · 2025Review
- The intersection of ferroptosis and non-coding RNAs: a novel approach to ovarian cancer.European journal of medical research · 2025Review
237 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 4 countries.
Funding
Abstract
The interplay between abnormalities in genes coding for proteins and noncoding microRNAs (miRNAs) has been among the most exciting yet unexpected discoveries in oncology over the last decade. The complexity of this network has redefined cancer research as miRNAs, produced from what was once considered "genomic trash," have shown to be crucial for cancer initiation, progression, and dissemination. Naturally occurring miRNAs are very short transcripts that never produce a protein or amino acid chain, but act by regulating protein expression during cellular processes such as growth, development, and differentiation at the transcriptional, posttranscriptional, and/or translational level. In this review article, miRNAs are presented as ubiquitous players involved in all cancer hallmarks. The authors also describe the most used methods to detect their expression, which have revealed the identity of hundreds of miRNAs dysregulated in cancer cells or tumor microenvironment cells. Furthermore, the role of miRNAs as hormones and as reliable cancer biomarkers and predictors of treatment response is discussed. Along with this, the authors explore current strategies in designing miRNA-targeting therapeutics, as well as the associated challenges that research envisions to overcome. Finally, a new wave in molecular oncology translational research is introduced: the study of long noncoding RNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.